Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decernotinib in active rheumatoid arthritis
NCT01754935Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jan 2013
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of decernotinib in rheumatoid arthritis (RA), sponsored by Vertex Pharmaceuticals. Started Jan 2013; status: completed.
02
Drugs
decernotinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01754935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01754935.